Abcam, ab189580, Human Osteoprotegerin ELISA Kit

Size: 1 x 96Tests
Human Osteoprotegerin ELISA Kit is a single-wash 90-min Simplestep used to quantify Human Osteoprotegerin with a sensitivity of 11 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair - Cited in over 5 citations
Key facts
Detection method:Colorimetric,
Sample types:Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 11 pg/mL,
Range:31.25 - 2000 pg/mL,
Assay time:1h 30m,
Assay Platform:Microplate

Product details:
Human Osteoprotegerin ELISA Kit (ab189580) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Osteoprotegerin protein in cell culture supernatant, cit plasma, edta plasma, hep plasma, and serum. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human Osteoprotegerin with 11 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
Human Osteoprotegerin (OPG), also known as Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a 46kDa glycoprotein member of the tumor necrosis factor receptor superfamily. This cytokine is a homodimer expressed and secreted by multiple adult tissues such as the lung, liver, spleen, prostate, ovary, adrenal gland and bone marrow. It plays a critical function in bone homeostasis by acting as a decoy receptor for TNFSF11/RANKL and for the receptor activator of nuclear factor-kappa-B ligand. OPG therefore decreases bone resorption by inhibiting osteoclast differentiation and activation of osteoclast and by stimulating osteoclast apoptosis.
OPG deficiency has been found in Juvenile Paget disease, a rare autosomal recessive osteopathy that presents in infancy and early childhood characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures and deformities due to accelerated bone remodeling. OPG may also play a role in arterial calcification and high levels of OPG have been found to be an independent risk factor for cardiovascular disease and vascular mortality.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Osteoprotegerin (OPG) also known as osteoclastogenesis inhibitory factor is a glycoprotein with a mass of approximately 60 kDa. It acts as a soluble decoy receptor for receptor activator of nuclear factor kappa-Β ligand (RANKL) and is encoded by the TNFRSF11B gene. OPG is mainly expressed in osteoblasts fibroblasts and endothelial cells. Its expression can be found in diverse tissues throughout the body including the liver and lungs.
Biological function summary
OPG inhibits the differentiation and activation of osteoclasts by binding to RANKL preventing its interaction with the receptor RANK on the surface of osteoclast progenitor cells. As part of a non-classical signaling pathway OPG plays a significant role in the regulation of bone remodeling and maintenance by controlling bone resorption. This activity preserves bone density and structure by limiting excessive osteoclastic activity.
Pathways
OPG operates within the RANK/RANKL/OPG signaling axis which is important for bone metabolism. It counteracts the bone-resorption pathway driven by the RANKL-RANK interaction inhibiting osteoclastogenesis. This axis involves interactions with other proteins such as RANK RANKL and TRAIL where TRAIL’s involvement hints towards a broader immune regulation role for OPG.
OPG has a significant association with conditions such as osteoporosis and vascular calcification. In osteoporosis an imbalance in the RANKL/OPG ratio can lead to excessive bone loss due to increased osteoclast activity. In vascular calcification OPG appears to play a protective role likely linked with regulatory mechanisms involving RANKL and TRAIL. Understanding these interactions opens potential therapeutic avenues particularly in managing bone-related and cardiovascular conditions.